Sunday, July 05, 2026

by Adam Irvine, Physicians Office Resource 

Introduction

Few topics in men's health have generated as much public attention in recent years as testosterone replacement therapy (TRT). Once reserved primarily for men with well-defined endocrine disorders, testosterone testing has become increasingly common in primary care, driven by aggressive direct-to-consumer advertising, telemedicine platforms specializing in "Low T," and widespread discussion across social media.

Today, physicians are routinely asked to evaluate men who attribute fatigue, diminished libido, reduced exercise capacity, weight gain, depressed mood, or cognitive difficulties to low testosterone.

While heightened awareness has encouraged many men to seek evaluation for previously unrecognized hypogonadism, it has also created a growing challenge for primary care physicians: distinguishing true testosterone deficiency from the physiologic effects of aging, obesity, chronic illness, medication use, sleep disorders, or lifestyle factors. Symptoms commonly associated with testosterone deficiency are often nonspecific, and indiscriminate testing or treatment may expose patients to unnecessary risks while overlooking the underlying cause of their complaints.

At the same time, legitimate hypogonadism remains underdiagnosed in certain populations, particularly among men with pituitary disease, primary testicular failure, hereditary conditions, or prior chemotherapy or radiation exposure. When appropriately identified and managed, testosterone replacement therapy can significantly improve sexual function, bone mineral density, body composition, anemia, and quality of life.

The role of the primary care physician has therefore become increasingly important. Rather than serving simply as gatekeepers to testosterone prescriptions, clinicians are uniquely positioned to conduct comprehensive evaluations, identify reversible causes of androgen deficiency, counsel patients regarding realistic expectations, and determine when hormone replacement is—or is not—clinically appropriate.

Current recommendations from the American Urological Association (AUA), the Endocrine Society, the American College of Physicians (ACP), and other professional organizations emphasize a consistent message: testosterone therapy should be reserved for men who demonstrate both persistent clinical symptoms and unequivocally low testosterone concentrations confirmed by appropriate laboratory testing. A diagnosis should never rest on symptoms alone or on a single laboratory value obtained under suboptimal conditions.

This article reviews current evidence regarding testosterone physiology, appropriate patient selection, laboratory evaluation, differential diagnosis, treatment considerations, monitoring strategies, and patient counseling to help primary care physicians navigate one of the most frequently requested—and frequently misunderstood—therapies in modern men's health.

 

Testosterone Physiology: Understanding the Hypothalamic-Pituitary-Gonadal Axis

Successful evaluation of testosterone deficiency begins with an understanding of normal endocrine physiology.

Testosterone production is regulated through the hypothalamic-pituitary-gonadal (HPG) axis. Pulsatile secretion of gonadotropin-releasing hormone (GnRH) from the hypothalamus stimulates release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary gland. LH then stimulates Leydig cells within the testes to produce testosterone, while FSH primarily supports spermatogenesis through Sertoli cell function.

Approximately 95% of circulating testosterone is synthesized within the testes, with the remaining fraction derived from adrenal androgen precursors. Once released into circulation, testosterone exists in three forms:

• Approximately 40–50% is tightly bound to sex hormone-binding globulin (SHBG)
• About 50–60% is loosely bound to albumin
• Only 1–3% circulates as free (unbound) testosterone

Although free testosterone represents only a small fraction of total circulating hormone, it is generally considered the biologically active component capable of entering target tissues and activating androgen receptors. Albumin-bound testosterone is also considered bioavailable because of its relatively weak protein binding.

Understanding these fractions becomes clinically important when interpreting laboratory results in patients with conditions that significantly alter SHBG concentrations.

 

Age-Related Decline Versus Pathologic Hypogonadism

One of the greatest misconceptions surrounding testosterone is that declining levels represent an inevitable disease requiring hormone replacement.

Beginning around the fourth decade of life, serum testosterone gradually declines at an average rate of approximately 1% annually, although substantial individual variation exists. Importantly, much of the observed decline appears related not simply to aging itself but to the increasing prevalence of obesity, metabolic syndrome, type 2 diabetes, chronic illness, reduced physical activity, and medication use.

Studies have demonstrated that healthy older men without significant comorbid disease often maintain testosterone concentrations within the normal physiologic range well into later adulthood. Conversely, obesity and chronic disease may suppress testosterone production in considerably younger individuals.

For this reason, professional societies increasingly distinguish organic hypogonadism, resulting from irreversible dysfunction of the testes or pituitary gland, from functional hypogonadism, in which testosterone production is suppressed secondary to potentially reversible medical conditions.

This distinction has important therapeutic implications. Men with organic hypogonadism frequently require lifelong testosterone replacement, whereas many patients with functional hypogonadism experience significant improvement following treatment of the underlying disorder.

 

When Should Physicians Order Testosterone Testing?

One of the most common errors in clinical practice is ordering testosterone levels in men without symptoms suggestive of androgen deficiency.

The Endocrine Society specifically recommends against routine screening of asymptomatic men. Instead, laboratory evaluation should be reserved for patients presenting with signs or symptoms consistent with testosterone deficiency.

Symptoms with the greatest diagnostic value include:

• Decreased libido
• Reduced frequency of spontaneous morning erections
• Erectile dysfunction
• Infertility
• Reduced sexual thoughts
• Decreased energy or endurance
• Loss of muscle strength
• Reduced physical performance
• Depressed mood
• Difficulty concentrating
• Hot flashes
• Low-trauma fractures
• Reduced shaving frequency

Physical examination findings may include:

• Decreased body hair
• Gynecomastia
• Reduced muscle mass
• Increased visceral adiposity
• Small or soft testes
• Delayed puberty (in younger patients)
• Osteopenia or osteoporosis

Many of the symptoms that prompt testosterone testing—including fatigue, reduced motivation, and cognitive complaints—are highly nonspecific. Sleep deprivation, depression, hypothyroidism, anemia, chronic inflammatory disease, medication effects, and psychosocial stress frequently produce similar clinical presentations.

Consequently, testosterone testing should be viewed as one component of a comprehensive diagnostic evaluation rather than a screening tool for generalized fatigue.

 

Which Patients Merit Special Consideration?

Although routine screening is discouraged, several patient populations warrant a lower threshold for evaluation because of their increased risk of hypogonadism.

These include men with:

• Type 2 diabetes mellitus
• HIV infection
• Osteoporosis or fragility fractures
• Chronic opioid therapy
• Pituitary disorders
• Prior pituitary surgery or radiation
• Klinefelter syndrome
• Bilateral orchiectomy
• Testicular trauma
• Chemotherapy exposure
• Chronic glucocorticoid use
• Hemochromatosis
• Infertility

Among these populations, identifying testosterone deficiency may significantly influence long-term management.

 

Functional Causes of Low Testosterone: Looking Beyond the Laboratory Value

Perhaps the most important clinical concept for primary care physicians is recognizing that low testosterone frequently reflects an underlying systemic condition rather than isolated endocrine disease.

 

Obesity

Obesity has emerged as one of the strongest predictors of reduced testosterone concentrations.

Adipose tissue contains aromatase, an enzyme that converts testosterone into estradiol. Increased estradiol suppresses hypothalamic GnRH secretion, ultimately reducing LH stimulation of the testes. In addition, chronic inflammation, insulin resistance, leptin dysregulation, and altered SHBG production contribute to functional suppression of testosterone.

Importantly, multiple studies have demonstrated that clinically significant weight loss can substantially improve endogenous testosterone production without hormone replacement.

As the use of GLP-1 receptor agonists and dual GIP/GLP-1 agonists continues to expand, physicians may increasingly observe normalization of testosterone concentrations following successful weight reduction. Consequently, obesity should be viewed as a potentially reversible contributor to hypogonadism rather than an automatic indication for TRT.

 

Type 2 Diabetes and Metabolic Syndrome

Approximately one-third of men with type 2 diabetes exhibit biochemical evidence of testosterone deficiency.

Insulin resistance, chronic inflammation, obesity, and endothelial dysfunction all contribute to suppression of the HPG axis.

Although testosterone therapy may improve body composition and modestly improve insulin sensitivity in selected patients with confirmed hypogonadism, optimization of diabetes management, exercise, nutrition, and weight reduction remain first-line interventions.

 

Obstructive Sleep Apnea

Obstructive sleep apnea represents another frequently overlooked cause of functional testosterone deficiency.

Normal testosterone secretion depends heavily on uninterrupted sleep architecture, particularly rapid eye movement (REM) sleep. Sleep fragmentation and intermittent hypoxia reduce nocturnal testosterone production.

Untreated sleep apnea may also increase cardiovascular risk independently of testosterone status.

Physicians should therefore evaluate patients with obesity, loud snoring, witnessed apneas, excessive daytime somnolence, or resistant hypertension for sleep-disordered breathing before initiating testosterone therapy.

 

Chronic Illness

Acute illness temporarily suppresses testosterone production through adaptive endocrine mechanisms.

Similarly, chronic inflammatory diseases, chronic kidney disease, liver disease, malignancy, uncontrolled heart failure, and autoimmune disorders may produce persistent reductions in testosterone concentrations.

Treating the underlying disease frequently produces greater clinical benefit than hormone replacement alone.

 

Medication-Induced Testosterone Suppression

Several commonly prescribed medications interfere with testosterone production.

Among the most important are:

• Chronic opioid therapy
• Systemic glucocorticoids
• Anabolic steroid withdrawal
• Certain antipsychotic medications
• Some anticonvulsants
• GnRH analogues
• Certain chemotherapy agents

A careful medication history should therefore precede any decision regarding hormone replacement.

 

Obtaining Accurate Testosterone Measurements

The diagnosis of hypogonadism depends as much on proper laboratory technique as on interpretation.

Testosterone secretion follows a circadian rhythm, with peak concentrations occurring during the early morning hours. Although diurnal variation diminishes somewhat with aging, morning testing remains the standard.

Current guidelines recommend:

• Measuring total testosterone between approximately 7:00 and 10:00 a.m.
• Testing while fasting whenever practical
• Avoiding measurement during acute illness or hospitalization
• Confirming low values with a second morning measurement obtained on a separate day using a reliable assay

The AUA recommends using a total testosterone level below 300 ng/dL as a reasonable biochemical threshold in symptomatic men. However, clinicians should recognize that laboratory-specific reference ranges vary, and testosterone values should always be interpreted in conjunction with clinical findings rather than in isolation.

Reliance on a single afternoon testosterone measurement remains one of the most common causes of both overdiagnosis and underdiagnosis in clinical practice.

 

Total Testosterone or Free Testosterone?

For most patients, total testosterone represents the preferred initial laboratory test.

However, free testosterone measurement may provide additional diagnostic value when SHBG abnormalities are suspected or when total testosterone concentrations are borderline despite persistent symptoms.

Conditions associated with altered SHBG include:

• Obesity
• Advanced age
• Hyperthyroidism
• Liver disease
• HIV infection
• Nephrotic syndrome
• Certain anticonvulsants
• Estrogen therapy

When indicated, calculated free testosterone derived from equilibrium dialysis or validated algorithms generally provides greater clinical reliability than many commercially available direct free testosterone immunoassays.

 

Determining the Cause: Primary vs. Secondary Hypogonadism

Confirming low serum testosterone is only the beginning of the diagnostic process. Once biochemical hypogonadism has been established with two appropriately obtained morning testosterone measurements, the next clinical objective is identifying the underlying cause. Distinguishing between primary and secondary hypogonadism has important implications for treatment, fertility counseling, prognosis, and the potential need for subspecialty referral.

 

Primary hypogonadism (hypergonadotropic hypogonadism) results from intrinsic testicular dysfunction. Because the testes fail to produce adequate testosterone despite normal pituitary stimulation, serum luteinizing hormone (LH) and follicle-stimulating hormone (FSH) concentrations are typically elevated.

Common causes include:

• Klinefelter syndrome
• Bilateral orchiectomy
• Testicular trauma
• Mumps orchitis
• Chemotherapy or pelvic radiation
• Undescended testes
• Advanced testicular atrophy

In contrast, secondary hypogonadism (hypogonadotropic hypogonadism) arises from impaired hypothalamic or pituitary signaling. Testosterone levels are low, but LH and FSH concentrations remain low or inappropriately normal.

Potential causes include:

• Pituitary adenomas
• Hyperprolactinemia
• Infiltrative pituitary disorders
• Head trauma
• Cranial irradiation
• Severe obesity
• Chronic systemic illness
• Chronic opioid therapy
• Hemochromatosis
• Congenital GnRH deficiency

Because secondary hypogonadism may reflect an underlying intracranial disorder, physicians should remain vigilant for symptoms such as headaches, visual field deficits, galactorrhea, or multiple pituitary hormone deficiencies.

 

Recommended Laboratory Evaluation Beyond Testosterone

A diagnosis of hypogonadism should rarely rely on testosterone measurement alone.

Following confirmation of low testosterone, additional laboratory evaluation generally includes:

• Luteinizing hormone (LH)
• Follicle-stimulating hormone (FSH)
• Prolactin
• Complete blood count
• Comprehensive metabolic panel
• Thyroid-stimulating hormone (TSH)
• Iron studies or ferritin when hemochromatosis is suspected
• Estradiol when gynecomastia or obesity is present
• Semen analysis in men undergoing fertility evaluation

Markedly elevated prolactin levels warrant further evaluation for pituitary disease, while persistent secondary hypogonadism without an obvious explanation may justify magnetic resonance imaging (MRI) of the pituitary gland.

Additional endocrine testing should be individualized according to the patient's presentation, age, fertility goals, and associated medical conditions.

 

When Is Testosterone Replacement Clinically Appropriate?

One of the strongest messages across all major clinical guidelines is that testosterone therapy should not be prescribed solely because of a laboratory result or because a patient requests treatment.

Instead, appropriate candidates meet both of the following criteria:

• Persistent symptoms or physical findings consistent with testosterone deficiency
• Repeatedly low morning testosterone concentrations confirmed using reliable laboratory methods

The presence of only one criterion is insufficient.

For example, an asymptomatic man with a testosterone concentration of 260 ng/dL generally should not receive treatment, while a symptomatic patient with normal testosterone levels requires investigation for alternative diagnoses rather than empiric testosterone replacement.

 

Patients Most Likely to Benefit

Evidence supports testosterone replacement in carefully selected men with established androgen deficiency, including those with:

• Primary testicular failure
• Pituitary disease
• Klinefelter syndrome
• Bilateral orchiectomy
• Chemotherapy-induced gonadal failure
• Radiation-induced hypogonadism
• Symptomatic congenital hypogonadism

Selected older men with persistent symptoms and unequivocally low testosterone levels may also benefit following comprehensive discussion of potential risks and expected benefits.

However, clinicians should avoid viewing testosterone as an anti-aging therapy. Current evidence does not support prescribing testosterone solely to improve vitality, athletic performance, cognition, or age-related declines in physical function among otherwise eugonadal men.

 

Contraindications to Testosterone Therapy

Before initiating therapy, physicians should carefully evaluate for contraindications.

Absolute or strong relative contraindications include:

• Men actively attempting conception
• Known or suspected prostate cancer without specialist evaluation
• Male breast cancer
• Hematocrit greater than 54%
• Untreated severe obstructive sleep apnea
• Uncontrolled heart failure
• Recent myocardial infarction or stroke
• Severe lower urinary tract symptoms until appropriately evaluated

Many of these conditions require individualized risk-benefit assessment rather than automatic exclusion. Shared decision-making remains essential.

 

Choosing the Appropriate Testosterone Formulation

Multiple FDA-approved testosterone formulations are available, allowing treatment to be tailored to patient preferences, insurance coverage, lifestyle, and clinical goals.

 

Intramuscular Testosterone

Testosterone cypionate and testosterone enanthate remain among the most frequently prescribed preparations.

Advantages include:

• Relatively low cost
• Familiarity among clinicians
• Flexible dosing intervals

Potential disadvantages include fluctuating testosterone concentrations, with supraphysiologic peaks shortly after injection followed by trough levels before the next dose. Some patients report corresponding fluctuations in mood, libido, or energy.

 

Long-Acting Injectable Testosterone

Testosterone undecanoate provides more stable serum concentrations and requires less frequent administration.

Although convenient for many patients, it must generally be administered in certified healthcare settings because of rare risks of pulmonary oil microembolism and anaphylaxis.

 

Transdermal Gels

Topical gels provide physiologic daily replacement with relatively stable hormone concentrations.

Benefits include:

• Avoidance of injections
• Steady testosterone levels
• Flexible dose adjustments

Patients should receive careful counseling regarding secondary transfer to partners, children, or other household contacts through skin-to-skin exposure before the medication dries completely.

 

Transdermal Patches

Patches offer another noninvasive option and provide consistent hormone delivery.

However, localized skin irritation remains a common reason for discontinuation.

 

Subcutaneous Pellets

Implanted pellets provide sustained testosterone release for approximately three to six months.

Advantages include improved adherence and convenience.

Disadvantages include the need for minor surgical insertion, occasional pellet extrusion, infection risk, and limited flexibility for dose adjustments.

 

Oral Testosterone

Newer oral testosterone undecanoate formulations have expanded treatment options while avoiding the hepatic toxicity associated with older oral alkylated testosterone preparations.

Because oral formulations remain relatively new, physicians should become familiar with formulation-specific monitoring recommendations and insurance coverage considerations.

 

What Benefits Should Physicians Expect?

Clinical improvement depends upon appropriate patient selection and realistic expectations.

Sexual symptoms often improve first, whereas changes in body composition and bone mineral density develop more gradually over months to years.

Randomized clinical trials have demonstrated improvements in:

 

Sexual Function

Among symptomatic hypogonadal men, testosterone replacement consistently improves libido and sexual desire. Erectile function may also improve, particularly when combined with phosphodiesterase-5 inhibitors in men with concurrent erectile dysfunction.

 

Body Composition

Testosterone therapy generally increases lean body mass while reducing visceral adiposity.

However, testosterone should not be considered a weight-loss medication. Lifestyle modification remains essential for long-term cardiometabolic improvement.

 

Bone Health

Long-term testosterone replacement increases bone mineral density, particularly within the lumbar spine.

These improvements may reduce fracture risk in appropriately selected patients, although fracture prevention data remain limited.

 

Anemia

The Testosterone Trials demonstrated meaningful improvement in unexplained anemia among hypogonadal older men receiving testosterone replacement.

 

Mood and Quality of Life

Many patients report improvements in mood, motivation, vitality, and overall well-being. Nevertheless, physicians should avoid presenting testosterone as primary treatment for depression or cognitive impairment, as improvements vary considerably among individuals.

 

Cardiovascular Safety: Where Does the Evidence Stand Today?

Few aspects of testosterone therapy have generated more controversy than cardiovascular safety.

Earlier observational studies suggested both increased and decreased cardiovascular risk, leading to considerable uncertainty and FDA safety communications during the past decade.

More recently, higher-quality randomized evidence has substantially clarified this issue.

The TRAVERSE Trial, published in 2023, enrolled more than 5,000 middle-aged and older men with symptomatic hypogonadism and either established cardiovascular disease or elevated cardiovascular risk.

After a median follow-up of approximately 33 months, investigators found that testosterone replacement was noninferior to placebo regarding major adverse cardiovascular events, including myocardial infarction, stroke, and cardiovascular death.

Although the study did identify small increases in certain adverse events—including atrial fibrillation, acute kidney injury, and pulmonary embolism—the overall findings provide reassurance that appropriately prescribed testosterone therapy does not appear to substantially increase major cardiovascular risk in carefully selected men.

For primary care physicians, the practical message is clear: cardiovascular disease alone should not automatically preclude testosterone therapy, but treatment should occur only after careful patient selection, optimization of cardiovascular risk factors, and shared decision-making.

 

Fertility: An Often Overlooked Counseling Point

One of the most important discussions before initiating testosterone therapy concerns fertility.

Many patients mistakenly believe testosterone replacement improves fertility because it increases serum testosterone concentrations.

The opposite is generally true.

Exogenous testosterone suppresses hypothalamic GnRH secretion, resulting in reduced LH and FSH production. Consequently, intratesticular testosterone levels fall dramatically, impairing spermatogenesis.

Some men develop severe oligospermia or complete azoospermia within months of treatment.

Men who desire future fertility should generally avoid testosterone replacement.

Alternative therapies—including selective estrogen receptor modulators (SERMs), aromatase inhibitors in selected cases, or human chorionic gonadotropin (hCG)—may preserve endogenous testosterone production and fertility under specialist supervision.

For younger patients, this conversation should occur before the first prescription is written.

 

Prostate Health: Separating Evidence from Myth

For decades, physicians avoided testosterone therapy because of concern that it might initiate prostate cancer.

Current evidence paints a far more nuanced picture.

No convincing evidence demonstrates that physiologic testosterone replacement causes prostate cancer in appropriately screened men.

However, testosterone may stimulate growth of existing androgen-sensitive prostate tissue. Consequently, clinicians should perform age-appropriate prostate cancer screening and discuss PSA monitoring before initiating therapy.

Men with untreated or active prostate cancer generally require evaluation by a urologist before considering testosterone replacement.

Similarly, men experiencing rapidly rising PSA concentrations or abnormal digital rectal examination findings should undergo appropriate urologic assessment before treatment continues.

Monitoring Patients Receiving Testosterone Therapy

Initiating testosterone replacement therapy is not the end of the clinical evaluation—it marks the beginning of an ongoing therapeutic relationship. Regular follow-up is essential to ensure treatment remains both effective and safe, allowing clinicians to optimize symptom relief while minimizing adverse effects.

Although monitoring recommendations vary slightly among professional organizations, most guidelines recommend reassessment approximately three months after therapy initiation, again at six to twelve months, and annually thereafter once the patient has achieved stable therapeutic levels.

At each follow-up visit, physicians should assess not only laboratory values but also whether the patient's original symptoms have improved. Testosterone therapy should not be continued indefinitely in men who fail to derive meaningful clinical benefit despite normalization of serum testosterone concentrations.

Routine follow-up should include evaluation of:

• Symptom improvement
• Adverse effects
• Medication adherence
• Blood pressure
• Weight and waist circumference
• Total testosterone concentration
• Hemoglobin and hematocrit
• Prostate-specific antigen (PSA), when age-appropriate
• Digital rectal examination according to current prostate cancer screening recommendations

The goal is not simply to normalize laboratory values, but rather to achieve mid-normal physiologic testosterone concentrations while improving quality of life and minimizing treatment-related complications.

 

Managing Polycythemia: The Most Common Clinically Significant Adverse Effect

Among all potential complications of testosterone replacement, erythrocytosis remains the most common and one of the most clinically important.

Testosterone stimulates erythropoiesis through several mechanisms, including increased erythropoietin production and suppression of hepcidin, leading to greater red blood cell production. While correction of unexplained anemia can be beneficial, excessive increases in hematocrit may increase blood viscosity and potentially elevate thromboembolic risk.

Professional guidelines recommend obtaining a baseline hemoglobin and hematocrit before initiating therapy and repeating measurements periodically throughout treatment.

If the hematocrit rises above 54%, clinicians should promptly evaluate contributing factors such as dehydration, smoking, chronic hypoxia, or untreated obstructive sleep apnea. Depending on the clinical scenario, management may include:

• Reducing the testosterone dose
• Extending the dosing interval
• Switching to a formulation associated with less erythrocytosis
• Temporarily discontinuing therapy
• Referral for therapeutic phlebotomy in selected cases

Injectable testosterone preparations generally produce erythrocytosis more frequently than transdermal formulations because of higher peak serum concentrations.

 

Managing Other Potential Adverse Effects

Although testosterone therapy is generally well tolerated in appropriately selected patients, physicians should remain attentive to other possible adverse effects.

 

Acne and Skin Changes

Increased sebaceous gland activity may lead to acne or oily skin, particularly during the first several months of therapy. Symptoms often improve with dose adjustment or conservative dermatologic management.

 

Gynecomastia

Conversion of testosterone to estradiol through aromatization may contribute to breast tenderness or gynecomastia in susceptible individuals. Significant symptoms warrant reassessment of dosing and consideration of alternative treatment strategies.

 

Fluid Retention

Mild peripheral edema occasionally develops, particularly in patients with underlying heart failure or chronic kidney disease. New or worsening edema should prompt evaluation for other cardiovascular causes before attributing symptoms solely to testosterone therapy.

 

Mood Changes

Most patients experience stable or improved mood; however, supraphysiologic testosterone concentrations may contribute to irritability, mood lability, or aggression. These symptoms are more commonly associated with excessive dosing than with physiologic replacement.

 

Sleep Apnea

The relationship between testosterone therapy and obstructive sleep apnea remains complex. Current evidence does not support routine discontinuation in patients with adequately treated sleep apnea, but untreated severe disease should generally be addressed before initiating testosterone replacement.

 

 

Lifestyle Modification: The Foundation of Testosterone Health

One of the most important messages physicians can communicate is that testosterone levels frequently reflect overall health.

In many patients, particularly those with obesity or metabolic syndrome, lifestyle interventions improve endogenous testosterone production while simultaneously reducing cardiovascular risk and improving overall health.

Evidence consistently supports the following interventions:

• Sustained weight reduction
• Resistance training
• Regular aerobic exercise
• Improved sleep quality
• Treatment of obstructive sleep apnea
• Smoking cessation
• Limiting excessive alcohol consumption
• Optimization of diabetes and hypertension management

The increasing use of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists has further emphasized this relationship. Significant weight loss achieved through pharmacologic therapy or bariatric surgery has been associated with meaningful increases in endogenous testosterone production in many men with obesity-related functional hypogonadism.

Consequently, physicians should present testosterone therapy not as a substitute for lifestyle modification, but as one component of a comprehensive approach to men's health when clinically indicated.

 

Shared Decision-Making: Setting Realistic Expectations

Perhaps the greatest determinant of long-term satisfaction with testosterone therapy is establishing realistic expectations before treatment begins.

Patients should understand that testosterone replacement is unlikely to transform energy levels overnight or reverse every symptom associated with aging. Improvements typically occur gradually, and the degree of benefit varies considerably among individuals.

Clinicians should discuss:

• Expected timeline of symptom improvement
• Need for ongoing laboratory monitoring
• Fertility implications
• Potential adverse effects
• Long-term treatment commitment
• Alternative treatment options
• Uncertainty surrounding certain long-term outcomes

Shared decision-making allows patients to weigh potential benefits against risks while ensuring therapy aligns with their individual goals and values.

 

Clinical Pearls for Primary Care Physicians

• Do not diagnose hypogonadism based on symptoms alone. Fatigue, low mood, and decreased energy have numerous potential causes.

 

• Confirm low testosterone with two separate early-morning measurements. A single abnormal value is insufficient for diagnosis.

 

• Always search for reversible causes. Obesity, obstructive sleep apnea, diabetes, chronic illness, opioid therapy, and glucocorticoids commonly suppress testosterone production.

 

• Measure LH and FSH after confirming low testosterone. Differentiating primary from secondary hypogonadism guides subsequent evaluation and management.

 

• Discuss fertility before prescribing testosterone. Exogenous testosterone suppresses spermatogenesis and may lead to temporary or prolonged infertility.

 

• Monitor hematocrit regularly. Polycythemia remains the most common clinically significant adverse effect.

 

• Do not prescribe testosterone as an anti-aging therapy. Treatment should be reserved for men with consistent symptoms and confirmed biochemical hypogonadism.

 

• View low testosterone as a clinical clue—not always the final diagnosis. In many patients, it serves as a marker of underlying metabolic disease rather than an isolated endocrine disorder.

 

Conclusion

Testosterone deficiency represents one of the most frequently discussed—and increasingly requested—conditions encountered in contemporary primary care. Heightened public awareness has encouraged more men to seek evaluation for symptoms affecting their quality of life, but it has also contributed to misconceptions regarding the diagnosis and treatment of hypogonadism.

For physicians, the challenge lies in distinguishing true androgen deficiency from the far more common functional suppression of testosterone associated with obesity, metabolic syndrome, chronic illness, medication use, and normal physiologic aging. Careful history taking, targeted physical examination, appropriate laboratory testing, and thoughtful evaluation of reversible causes remain the cornerstones of evidence-based diagnosis.

Current clinical guidelines are remarkably consistent: testosterone replacement therapy should be reserved for men with persistent symptoms of androgen deficiency and unequivocally low testosterone concentrations confirmed on repeated morning measurements. Treatment should never be initiated solely on the basis of a single laboratory value or patient request.

When appropriately prescribed, testosterone therapy can meaningfully improve sexual function, bone health, body composition, anemia, and overall quality of life. Equally important, however, is recognizing when treatment is unlikely to provide benefit or when addressing underlying obesity, sleep apnea, diabetes, depression, medication effects, or other comorbidities may be the more effective intervention.

As direct-to-consumer hormone clinics and online prescribing platforms continue to expand, primary care physicians remain uniquely positioned to provide comprehensive, evidence-based care rooted in clinical judgment rather than marketing. By combining guideline-directed evaluation with shared decision-making and ongoing monitoring, clinicians can help ensure that testosterone therapy is used safely, appropriately, and in the patients most likely to benefit.

References

1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.
2. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: American Urological Association Guideline. J Urol. 2018;200(2):423-432. Updated 2024.
3. Qaseem A, Horwitch CA, Vijan S, et al. Testosterone treatment in adult men with age-related low testosterone: A clinical guideline from the American College of Physicians. Ann Intern Med. 2020;172(2):126-133.
4. Lincoff AM, Nissen SE, Bhasin S, et al.; TRAVERSE Study Investigators. Cardiovascular safety of testosterone replacement therapy in men with hypogonadism. N Engl J Med. 2023;389:107-117.
5. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-624.
6. Corona G, Goulis DG, Huhtaniemi I, et al. European Academy of Andrology guidelines on investigation, treatment, and monitoring of functional hypogonadism in males. Andrology. 2020;8(5):970-987.
7. Handelsman DJ. Free testosterone: Pumping up the tires or ending the free ride? Endocr Rev. 2017;38(4):297-301.
8. Grossmann M. Hypogonadism and male obesity: Focus on unresolved questions. Clin Endocrinol (Oxf). 2018;89(1):11-21.
9. Kelly DM, Jones TH. Testosterone and obesity. Obes Rev. 2015;16(7):581-606.
10. Morgentaler A, Miner MM, Caliber M, et al. Testosterone therapy and prostate cancer: An updated review of evidence and clinical recommendations. Mayo Clin Proc. 2024;99(2):267-281.